Repligen Co. (NASDAQ:RGEN) Stake Cut by New York State Common Retirement Fund

New York State Common Retirement Fund cut its stake in Repligen Co. (NASDAQ:RGEN) by 4.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 425,412 shares of the biotechnology company’s stock after selling 17,676 shares during the period. New York State Common Retirement Fund owned 0.76% of Repligen worth $76,489,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. abrdn plc increased its position in Repligen by 1.4% in the fourth quarter. abrdn plc now owns 5,192 shares of the biotechnology company’s stock worth $934,000 after buying an additional 71 shares during the period. Signaturefd LLC increased its holdings in shares of Repligen by 44.1% during the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 86 shares during the period. First Horizon Advisors Inc. increased its holdings in shares of Repligen by 14.8% during the third quarter. First Horizon Advisors Inc. now owns 675 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 87 shares during the period. Daiwa Securities Group Inc. increased its holdings in shares of Repligen by 3.2% during the third quarter. Daiwa Securities Group Inc. now owns 3,200 shares of the biotechnology company’s stock valued at $509,000 after purchasing an additional 100 shares during the period. Finally, State of Michigan Retirement System increased its holdings in shares of Repligen by 0.8% during the fourth quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock valued at $2,239,000 after purchasing an additional 100 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Repligen

In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the sale, the vice president now directly owns 24,260 shares in the company, valued at approximately $4,699,889.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Repligen news, CEO Anthony Hunt sold 16,707 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the sale, the chief executive officer now directly owns 185,249 shares in the company, valued at approximately $36,575,562.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Ralf Kuriyel sold 3,517 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the sale, the vice president now owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The disclosure for this sale can be found here. Insiders sold 25,597 shares of company stock worth $5,039,532 in the last quarter. 1.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

RGEN has been the topic of a number of research analyst reports. Stifel Nicolaus raised their price target on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. KeyCorp raised their price target on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Repligen presently has a consensus rating of “Moderate Buy” and a consensus target price of $196.70.

Repligen Price Performance

NASDAQ:RGEN opened at $171.28 on Wednesday. The business’s 50-day moving average price is $186.62 and its 200 day moving average price is $173.56. The firm has a market cap of $9.56 billion, a P/E ratio of 237.89, a PEG ratio of 5.16 and a beta of 1.02. Repligen Co. has a 52-week low of $110.45 and a 52-week high of $211.13. The company has a quick ratio of 5.75, a current ratio of 7.02 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The business had revenue of $155.74 million during the quarter, compared to analyst estimates of $155.38 million. During the same quarter last year, the company posted $0.68 EPS. Repligen’s revenue for the quarter was down 16.6% on a year-over-year basis. As a group, sell-side analysts predict that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.